The Guangdong Provincial Key Laboratory of Non-Clinical Drug Evaluation and Research is a joint initiative established by Lewwin Pharm, Sun Yat-sen University, Guangzhou Bay Area Institute of Biomedicine, The Fifth Affiliated Hospital of Southern Medical University, and Guangzhou Dongyuan Pharmaceutical Technology Co., Ltd. This collaboration integrates the advantageous resources of the five parties to address the needs of industrial development, overcome technical challenges in non-clinical drug evaluation research, and break down international barriers.

Closely aligned with the strategic development needs of both the international biomedical industry and the Guangdong-Hong Kong-Macao Greater Bay Area biomedical sector, the Laboratory focuses on tackling key and challenging technologies essential for non-clinical drug evaluation research. Building upon its established systems, including cell-based drug evaluation technologies, macromolecular drug pharmacokinetics, reproductive substitution, chiral drug pharmacokinetics, carcinogenicity testing, and pediatric and ophthalmic drug evaluation. The Laboratory directs its efforts toward areas such as gene therapy nucleic acid drugs, CiPA (comprehensive in vitro proarrhythmia assay), reproductive substitution, domestically developed alternatives for carcinogenicity testing, anti-infective drugs, and vaccines. Through these efforts, the Laboratory aims to break down international barriers and enhance its competitiveness in the global arena.